BamSEC and AlphaSense Join Forces
Learn More
You must log in to view this page.

Scribe Therapeutics Inc. – Material Contracts

NASDAQ: SCTX    
Share price (8/10/26): $24.93    
Market cap (8/10/26): $403 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.18
from S-1/A 11 pages Stock Purchase Agreement
12/34/56
EX-10.13
from S-1/A 75 pages Article 1 Definitions
12/34/56
EX-10.8
from S-1/A 3 pages Scribe Therapeutics Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.4
from S-1/A 18 pages Scribe Therapeutics, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.3
from S-1/A 49 pages Scribe Therapeutics Inc. 2026 Equity Incentive Plan
12/34/56
EX-10.1
from S-1/A 14 pages Form of Indemnity Agreement
12/34/56
EX-10.17
from S-1 9 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Scribe Therapeutics Inc. if Publicly Disclosed
12/34/56
EX-10.16
from S-1 9 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Scribe Therapeutics Inc. if Publicly Disclosed
12/34/56
EX-10.15
from S-1 14 pages Scribe Therapeutics, Inc. Scientific Advisory Board Member Agreement
12/34/56
EX-10.14
from S-1 13 pages Scribe Therapeutics Inc. Scientific Advisory Board Member Agreement
12/34/56
EX-10.13
from S-1 66 pages Article 1 Definitions
12/34/56
EX-10.12
from S-1 76 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Scribe Therapeutics Inc. if Publicly Disclosed. License and Collaboration Agreement Between Scribe Therapeutics Inc. and Prevail Therapeutics, Inc. Dated as of May 11, 2023
12/34/56
EX-10.11
from S-1 90 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Scribe Therapeutics Inc. if Publicly Disclosed. Development and Option Agreement by and Between Acuitas Therapeutics, Inc. and Scribe Therapeutics Inc. Dated November 7, 2022
12/34/56
EX-10.10
from S-1 48 pages Amended and Restated Exclusive License Agreement Between Scribe Therapeutics Inc. and the Regents of the University of California for “Rna-Guided Nucleic Acid Modifying Enzymes and Methods of Use Thereof (“Casx”)” and “Rna-Guided Nucleic Acid Modifying Enzymes and Methods of Use Thereof
12/34/56
EX-10.9
from S-1 74 pages Marina Village Lease G&I IX Marina Village Office Park LP, a Delaware Limited Partnership as Landlord, and Scribe Therapeutics Inc., a Delaware Corporation as Tenant Summary of Basic Lease Information
12/34/56
EX-10.7
from S-1 19 pages Scribe Therapeutics Inc. May 8, 2023
12/34/56
EX-10.6
from S-1 20 pages Scribe Therapeutics Inc. September 11, 2022
12/34/56
EX-10.5
from S-1 21 pages Scribe Therapeutics Inc. October 12, 2021
12/34/56
EX-10.2
from S-1 49 pages Scribe Therapeutics Inc. 2018 Stock Incentive Plan
12/34/56
EX-10.17
from DRS/A 9 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Scribe Therapeutics Inc. if Publicly Disclosed
12/34/56